Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07221227 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

Name: A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH — clinical trial record (NCT07221227)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ZENITH-1

StatusRecruiting

PhasePhase 3

SponsorGlaxoSmithKline

Started2025-10-24

View on ClinicalTrials.gov ↗

The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.

Amendment history 1 change detected by DataLookout

2026-07-28

Trial sites expanded: 49 → 91 locations

Trial Details

NCT Number	NCT07221227
Lead Sponsor	GlaxoSmithKline
Conditions	Non-alcoholic Fatty Liver Disease
Enrollment	1,200 participants
Start Date	2025-10-24
Primary Completion	2028-03-29 (estimated)
Study Completion	2031-12-12 (estimated)
Updated on ClinicalTrials.gov	2026-07-27